Implanon use lowers plasma concentrations of high-molecular-weight adiponectin

Merki‐Feld, Gabriele S.; Imthurn, Bruno; Rosselli, Marinella; Spanaus, Katharina

doi:10.1016/j.fertnstert.2010.05.018

Cited by 6 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One study showed a decrease in mean adiponectin levels with short-term use of a progestin-only subdermal implant [24]. Another showed no change or a decrease in mean resistin levels in females taking COCs for 6 months [25].…”

Section: Discussionmentioning

confidence: 99%

Effect of a combined estrogen and progesterone oral contraceptive on circulating adipocytokines adiponectin, resistin and DLK-1 in normal and obese female rhesus monkeys

2013

View full text Add to dashboard Cite

Background Hormonal contraception is the most common medication used by reproductive aged women but there is little understanding of the impact of hormonal contraception on obesity and metabolism. Adipokine levels (adiponectin, resistin) and markers of adipocyte development (DLK-1) are altered in obese animals and humans and are associated with increased cardiovascular risk. We sought to determine the effect of combined hormonal oral contraceptive pills (COCs) on circulating adiponectin, resistin and DLK-1 levels in obese and normal-weight rhesus macaque monkeys. Methods Serum adiponectin, resistin and DLK-1 levels in reproductive-age female rhesus macaques of normal (n = 5, mean = 5.76 kg) and inherently obese (n = 5, mean = 8.11 kg) weight were determined before, during and 2 months after cessation of 8 months of continuous treatment with COCs. Results The obese group alone showed a significant decrease (p<.01) in weight with COC use, which returned to baseline after COC cessation. Baseline adiponectin levels prior to COC treatment were lower in the obese group (p<.05). Adiponectin levels increased from baseline in both groups, but more so in the obese group (p<.05). Resistin levels were similar at baseline, with an increase in both groups following treatment. Circulating resistin remained elevated above baseline levels after COC cessation, particularly in the obese group (p<.05). While DLK-1 levels did not change significantly in either group, a trend for higher levels in obese animals was observed. Conclusions COC use may alter metabolic processes via direct (resistin) or indirect (adiponectin) means, while unchanging DLK1 levels suggest they do not affect adipocyte development. COCs may directly increase resistin levels, as observed in both groups. As adiponectin is inversely related to adipocyte mass, increased levels in the obese group are likely attributed to weight loss.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of a combined estrogen and progesterone oral contraceptive on circulating adipocytokines adiponectin, resistin and DLK-1 in normal and obese female rhesus monkeys

2013

View full text Add to dashboard Cite

show abstract

“…Our results are consistent with previous data showing high SHBG levels among COC users (Raps et al, 2012;van Rooijen et al, 2004;van Vliet et al, 2005). By contrast, a decrease in SHBG levels has been reported among POC users (Barkfeldt et al, 2001;Mainwaring et al, 1995;Merki-Feld et al, 2011;Odlind et al, 2002;Raps et al, 2012). To our knowledge, this is the first study to investigate the influence of CMA contraceptive on plasma concentration of SHBG.…”

Section: Discussionmentioning

confidence: 75%

Sex hormone-binding globulin and thrombin generation in women using hormonal contraception

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In ovulatory women, the etonogestrel implant was shown to be associated with a reduction of testosterone and SHBG after 12 weeks of use. 19 The effect of POCs in women with PCOS, however, still requires investigation. Based on the existing clinical guidelines, a possible flow diagram of eligibility of hormonal contraceptives for women with PCOS is presented in Figure 1 .…”

Section: Noncontraceptive Benefits Of Hormonal Contraception In Womenmentioning

confidence: 99%

Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits

Melo¹,

Reis²,

Ferriani³

et al. 2017

OAJC

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is an endocrine disorder among women of reproductive age characterized by chronic anovulation and polycystic ovary morphology and/or hyperandrogenism. Management of clinical manifestations of PCOS, such as menstrual irregularities and hyperandrogenism symptoms, includes lifestyle changes and combined hormonal contraceptives (CHCs). CHCs contain estrogen that exerts antiandrogenic properties by triggering the hepatic synthesis of sex hormone-binding globulin that reduces the free testosterone levels. Moreover, the progestogen present in CHCs and in progestogen-only contraceptives suppresses luteinizing hormone secretion. In addition, some types of progestogens directly antagonize the effects of androgens on their receptor and also reduce the activity of the 5α reductase enzyme. However, PCOS is related to clinical and metabolic comorbidities that may limit the prescription of CHCs. Clinicians should be aware of risk factors, such as age, smoking, obesity, diabetes, systemic arterial hypertension, dyslipidemia, and a personal or family history, of a venous thromboembolic event or thrombophilia. This article reports a narrative review of the available evidence of the safety of hormonal contraceptives in women with PCOS. Considerations are made for the possible impact of hormonal contraceptives on endocrine, metabolic, and cardiovascular health.

show abstract

Implanon use lowers plasma concentrations of high-molecular-weight adiponectin

Cited by 6 publications

References 44 publications

Effect of a combined estrogen and progesterone oral contraceptive on circulating adipocytokines adiponectin, resistin and DLK-1 in normal and obese female rhesus monkeys

Effect of a combined estrogen and progesterone oral contraceptive on circulating adipocytokines adiponectin, resistin and DLK-1 in normal and obese female rhesus monkeys

Sex hormone-binding globulin and thrombin generation in women using hormonal contraception

Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits

Contact Info

Product

Resources

About